Pricing Log in Create free account
Friday 6 November 2026 Export IMNM’s income statement to Excel — free account

Immunome, Inc.

IMNM Healthcare Biotechnology

Immunome, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $6.9 million, down 23.2% from fiscal 2024.

Revenue
+69.8%
EPS
−30.0%
Free cash flow
−27.0%

Quarter to June 2026, against a year earlier

18.77 0.86 +4.80%
Market cap
$2.1B
P/E
0.0×
Fwd P/E
−7.6×
Dividend yield
—
F-score
4/9
Altman Z
21.57
Beneish M
n/a
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Immunome, Inc. (IMNM) P/E ratio

Alert me on P/E ratio

Immunome, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.

P/E ratio, daily

Embed this chart

Annual newest first

Period P/E ratio Change
FY2025 0.0× —
FY2024 0.0× —
FY2023 0.0× —

Quarterly newest first

Period P/E ratio Change
Jun 2025 0.0× —
Mar 2025 0.0× —
Dec 2024 0.0× —
Sep 2024 0.0× —
6 more quarters

Against its own ten years

Low 0.0× High 0.0×
Ten-year median 0.0×
Current reading's percentile 100

P/E ratio against peers

Company P/E ratio
PVLA Palvella Therapeutics, Inc. compare n/m
BHVN Biohaven Ltd. compare n/m
LKFT Lakefront Biotherapeutics - Sponsored ADR compare n/m
VERA Vera Therapeutics, Inc. compare n/m
CLDX Celldex Therapeutics, Inc. compare n/m
IMNM Immunome, Inc. n/m
AUPH Aurinia Pharmaceuticals Inc compare 6.8×
ADMA ADMA Biologics Inc compare 16.7×
VCEL Vericel Corporation compare 77.8×
Biotechnology industry median 10.3×
Healthcare sector median 25.2×
Market median 17.9×

What P/E ratio is

Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.

Stock Price ÷ EPS (Basic) (TTM)

The full definition of P/E ratio →

More on IMNM